Early findings show efficacy of water vapor therapy for treating intermediate-risk prostate cancer with minimal procedural ...
TORONTO, April 01, 2026 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets AI-powered, ...
LOS ANGELES, Nov. 07, 2023 (GLOBE NEWSWIRE) -- Clinical Laserthermia Systems Americas, Inc. (CLS), a leading provider of office-based, focal laser ablation (FLA) systems for urologists, and HALO ...
Francis’ ongoing VAPOR 2 single-arm study aims to support a 510(k) application for Vanquish at the FDA this July, with one-year data from 235 patients diagnosed with localized, intermediate-risk ...
LATHAM, N.Y.--(BUSINESS WIRE)-- AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, ...
The FDA’s 510(k) clearance was based in part on the company’s pivotal PRESERVE study, which reported 84% of men with no clinically significant disease after 12 months. (Photo by Sarah Silbiger/Getty ...
Prostate cancers are either low-grade, low-risk forms that may be monitored but otherwise untreated, or they’re serious enough to require surgery and radiation. Monitoring can cause patients anxiety.
(NASDAQ: ANGO), a medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options and improving patient quality of life, today ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results